Alfonso Corrales1, Nuria Vegas-Revenga2, Javier Rueda-Gotor3, Virginia Portilla4, Belén Atienza-Mateo5, Ricardo Blanco6, Santos Castañeda7, Iván Ferraz-Amaro8, Javier Llorca9, Miguel A González-Gay10. 1. Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain. Electronic address: afcorralesm@hotmail.com. 2. Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain. Electronic address: nuriavegas2@gmail.com. 3. Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain. Electronic address: ruedagotor@gmail.com. 4. Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain. Electronic address: virgiportilla@hotmail.com. 5. Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain. Electronic address: mateoatienzabelen@gmail.com. 6. Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain. Electronic address: ricardo.blanco@scsalud.es. 7. Division of Rheumatology, Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Spain. Electronic address: scastas@gmail.com. 8. Division of Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain. Electronic address: iferrazamaro@hotmail.com. 9. University of Cantabria - IDIVAL, Santander, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain. Electronic address: llorcaj@unican.es. 10. Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain; Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain; University of Cantabria, Santander, Spain; University of the Witwatersrand, Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, South Africa. Electronic address: miguelaggay@hotmail.com.
Abstract
OBJECTIVE: To investigate if the Systematic Coronary Risk Evaluation (SCORE) and the QRISK3 algorithms as well as the carotid ultrasound are useful predictors of cardiovascular (CV) events and death in a prospectively defined population-based rheumatoid arthritis (RA) inception cohort. METHODS: A set of 327 consecutive RA patients without history of diabetes, chronic kidney disease or CV events were studied by carotid ultrasound between 2012 and 2013. At that time, CV risk was calculated according to the modified EULAR systematic coronary risk evaluation (mSCORE) for RA. A five-year prospective follow-up study was conducted by survival analysis models. The EULAR mSCORE based on the 2015/2016 updated EULAR recommendations and the QRISK3 algorithms were retrospectively tested using baseline data. RESULTS: After 1,984.25 patient-years of follow-up, 23 had died and 27 had experienced CV events. Linearized mortality rate was 1.16/100 patient-years (95% confidence interval [CI]: 0.74--1.73). Adjusting for age, gender and disease duration, a model with carotid plaques (Hazard ratio [HR]: 6.10 [95% CI:0.74--50.0]; p = 0.09) and another model with carotid plaques and QRISK3 (HR for carotid plaques: 6.12 [95% CI: 0.74--50.5]; p = 0.09 and HR for each 1% in QRISK3: 1.03 [95% CI: 0.99--1.07], p = 0.11, respectively were the best predictors of death whereas a model with carotid plaques (HR: 5.25 [95% CI:1.41--19.50]; p = 0.01) and another model with carotid plaques and QRISK3 (HR for carotid plaques: 5.13 [95% CI: 1.36--19.3]; p = 0.02 and HR for each 1% in QRISK3: 1.03 [95% CI: 0.99--1.07], p = 0.12, respectively, were the best predictors of CV events. In contrast, the mSCORE was a weaker predictor of the risk of death or CV events. CONCLUSIONS: The presence of carotid plaques predicts the development of CV events and death in patients with RA. The predictable capacity of carotid plaques and QRISK3 is higher than that of mSCORE in RA patients.
OBJECTIVE: To investigate if the Systematic Coronary Risk Evaluation (SCORE) and the QRISK3 algorithms as well as the carotid ultrasound are useful predictors of cardiovascular (CV) events and death in a prospectively defined population-based rheumatoid arthritis (RA) inception cohort. METHODS: A set of 327 consecutive RApatients without history of diabetes, chronic kidney disease or CV events were studied by carotid ultrasound between 2012 and 2013. At that time, CV risk was calculated according to the modified EULAR systematic coronary risk evaluation (mSCORE) for RA. A five-year prospective follow-up study was conducted by survival analysis models. The EULAR mSCORE based on the 2015/2016 updated EULAR recommendations and the QRISK3 algorithms were retrospectively tested using baseline data. RESULTS: After 1,984.25 patient-years of follow-up, 23 had died and 27 had experienced CV events. Linearized mortality rate was 1.16/100 patient-years (95% confidence interval [CI]: 0.74--1.73). Adjusting for age, gender and disease duration, a model with carotid plaques (Hazard ratio [HR]: 6.10 [95% CI:0.74--50.0]; p = 0.09) and another model with carotid plaques and QRISK3 (HR for carotid plaques: 6.12 [95% CI: 0.74--50.5]; p = 0.09 and HR for each 1% in QRISK3: 1.03 [95% CI: 0.99--1.07], p = 0.11, respectively were the best predictors of death whereas a model with carotid plaques (HR: 5.25 [95% CI:1.41--19.50]; p = 0.01) and another model with carotid plaques and QRISK3 (HR for carotid plaques: 5.13 [95% CI: 1.36--19.3]; p = 0.02 and HR for each 1% in QRISK3: 1.03 [95% CI: 0.99--1.07], p = 0.12, respectively, were the best predictors of CV events. In contrast, the mSCORE was a weaker predictor of the risk of death or CV events. CONCLUSIONS: The presence of carotid plaques predicts the development of CV events and death in patients with RA. The predictable capacity of carotid plaques and QRISK3 is higher than that of mSCORE in RApatients.
Authors: Juan Carlos Quevedo-Abeledo; Miguel Á González-Gay; Iván Ferraz-Amaro Journal: Ther Adv Musculoskelet Dis Date: 2022-04-19 Impact factor: 3.625
Authors: Miguel Á González-Gay; Iván Ferraz-Amaro; Laura de Armas-Rillo; Juan Carlos Quevedo-Abeledo; Vanesa Hernández-Hernández; Antonia de Vera-González; Alejandra González-Delgado; José A García-Dopico Journal: Arthritis Res Ther Date: 2022-04-29 Impact factor: 5.606
Authors: Iván Ferraz-Amaro; Alfonso Corrales; Belén Atienza-Mateo; Nuria Vegas-Revenga; Diana Prieto-Peña; Julio Sánchez-Martín; Cristina Almeida; Juan Carlos Quevedo-Abeledo; Ricardo Blanco; Miguel Á González-Gay Journal: Diagnostics (Basel) Date: 2021-12-15